Literature DB >> 11159515

mDYRK3 kinase is expressed selectively in late erythroid progenitor cells and attenuates colony-forming unit-erythroid development.

J N Geiger1, G T Knudsen, L Panek, A K Pandit, M D Yoder, K A Lord, C L Creasy, B M Burns, P Gaines, S B Dillon, D M Wojchowski.   

Abstract

DYRKs are a new subfamily of dual-specificity kinases that was originally discovered on the basis of homology to Yak1, an inhibitor of cell cycle progression in yeast. At present, mDYRK-3 and mDYRK-2 have been cloned, and mDYRK-3 has been characterized with respect to kinase activity, expression among tissues and hematopoietic cells, and possible function during erythropoiesis. In sequence, mDYRK-3 diverges markedly in noncatalytic domains from mDYRK-2 and mDYRK-1a, but is 91.3% identical overall to hDYRK-3. Catalytically, mDYRK-3 readily phosphorylated myelin basic protein (but not histone 2B) and also appeared to autophosphorylate in vitro. Expression of mDYRK-1a, mDYRK-2, and mDYRK-3 was high in testes, but unlike mDYRK1a and mDYRK 2, mDYRK-3 was not expressed at appreciable levels in other tissues examined. Among hematopoietic cells, however, mDYRK-3 expression was selectively elevated in erythroid cell lines and primary pro-erythroid cells. In developmentally synchronized erythroid progenitor cells, expression peaked sharply following exposure to erythropoietin plus stem cell factor (SCF) (but not SCF alone), and in situ hybridizations of sectioned embryos revealed selective expression of mDYRK-3 in fetal liver. Interestingly, antisense oligonucleotides to mDYRK-3 were shown to significantly and specifically enhance colony-forming unit-erythroid colony formation. Thus, it is proposed that mDYRK-3 kinase functions as a lineage-restricted, stage-specific suppressor of red cell development. (Blood. 2001;97:901-910)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159515     DOI: 10.1182/blood.v97.4.901

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Genome-wide identification of TAL1's functional targets: insights into its mechanisms of action in primary erythroid cells.

Authors:  Mira T Kassouf; Jim R Hughes; Stephen Taylor; Simon J McGowan; Shamit Soneji; Angela L Green; Paresh Vyas; Catherine Porcher
Journal:  Genome Res       Date:  2010-06-21       Impact factor: 9.043

2.  Developmental transcriptome analysis of human erythropoiesis.

Authors:  Lihong Shi; Yu-Hsuan Lin; M C Sierant; Fan Zhu; Shuaiying Cui; Yuanfang Guan; Maureen A Sartor; Osamu Tanabe; Kim-Chew Lim; James Douglas Engel
Journal:  Hum Mol Genet       Date:  2014-04-29       Impact factor: 6.150

3.  Splice variants of the dual specificity tyrosine phosphorylation-regulated kinase 4 (DYRK4) differ in their subcellular localization and catalytic activity.

Authors:  Chrisovalantis Papadopoulos; Krisztina Arato; Eva Lilienthal; Johannes Zerweck; Mike Schutkowski; Nicolas Chatain; Gerhard Müller-Newen; Walter Becker; Susana de la Luna
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

4.  Depleting Mirk Kinase Increases Cisplatin Toxicity in Ovarian Cancer Cells.

Authors:  Jing Hu; Eileen Friedman
Journal:  Genes Cancer       Date:  2010-08-01

5.  DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1.

Authors:  Xiumei Guo; Jason G Williams; Thaddeus T Schug; Xiaoling Li
Journal:  J Biol Chem       Date:  2010-02-18       Impact factor: 5.157

6.  Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species.

Authors:  Xiaobing Deng; Daina Z Ewton; Eileen Friedman
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

7.  DYRK3 dual-specificity kinase attenuates erythropoiesis during anemia.

Authors:  Olga Bogacheva; Oleg Bogachev; Madhu Menon; Arvind Dev; Estelle Houde; Elizabeth I Valoret; Haydn M Prosser; Caretha L Creasy; Susan J Pickering; Evelyn Grau; Kim Rance; George P Livi; Vinit Karur; Connie L Erickson-Miller; Don M Wojchowski
Journal:  J Biol Chem       Date:  2008-10-14       Impact factor: 5.157

8.  Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors.

Authors:  Christian Schmitt; Dagmar Kail; Marica Mariano; Martin Empting; Nadja Weber; Tamara Paul; Rolf W Hartmann; Matthias Engel
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

9.  Exposure to hypoxia causes stress erythropoiesis and downregulates immune response genes in spleen of mice.

Authors:  Haijing Wang; Daoxin Liu; Pengfei Song; Feng Jiang; Xiangwen Chi; Tongzuo Zhang
Journal:  BMC Genomics       Date:  2021-06-05       Impact factor: 3.969

10.  The Kinase Mirk/dyrk1B: A Possible Therapeutic Target in Pancreatic Cancer.

Authors:  Eileen Friedman
Journal:  Cancers (Basel)       Date:  2010-07-14       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.